Gerresheimer’s Paradox: Oversold Metrics Fight a Credibility Crisis as Audit Drags On

Pharma packaging firm Gerresheimer struggles with audit delay, short interest at 11.4%, and activist stake, but gets covenant waiver and pursues Centor sale.

The clouds over Gerresheimer refuse to lift. The pharma packaging specialist’s stock is technically oversold — the relative strength index stands at 28.1 — yet short sellers have piled in with a position of roughly 11.4% of outstanding shares. At the same time, activist investor Active Ownership has ramped its stake to 15.19%, while insiders have made open-market purchases that normally signal confidence. But without a signed audit report, none of those bullish cues carries full conviction.

A second external auditing firm has been brought in to examine prior-year balance-sheet items, pushing the release of a testated 2025 annual report into June 2026. That date has become the hard deadline for shareholder faith. Until then, the market will keep the stock on a short leash.

A Scrapped AGM and a Banking Lifeline

The absence of a testated financial statement has already forced Gerresheimer to cancel its annual general meeting, originally set for June 3. The meeting cannot legally proceed without the approved accounts. Management says a new date will be announced in June once the audit is complete.

Creditors have stepped in with breathing room. Banks have waived important debt covenants until September 30, 2026, relieving near-term pressure on the balance sheet. The concession gives interim CEO Uwe Röhrhoff time to steer through the cleanup. Non-cash impairments — expected in the three-digit million range, primarily for Sensile Medical projects — still need to be booked, but the covenant extension keeps financing lines open.

Centor Sale Takes Center Stage

Parallel to the accounting drama, Gerresheimer is pressing ahead with the divestiture of its U.S. subsidiary Centor, a manufacturer of drug packaging carried at a book value of €292 million. Morgan Stanley is running the auction, which has already attracted a double-digit number of interested parties. A deal is expected before the end of the calendar year.

Proceeds from the sale are viewed as the cornerstone of a deleveraging plan that also includes digesting the Bormioli acquisition. Fresh capital would strengthen Gerresheimer’s hand with banks and Schuldschein lenders, creating a cushion against further financial jolts.

Technology in the Background, Pressure Up Front

On an operational level, the company is not standing still. At the Interpack trade fair in Düsseldorf, Gerresheimer unveiled a concrete product from its partnership with U.S. chemical firm Milliken. The collaboration uses a special additive technology that improves the moisture barrier in plastic packaging by up to 40%. Yet such product news is currently drowned out by the noise around the balance sheet.

Management has held on to its full-year guidance, targeting revenue of up to €2.4 billion and an operating margin of roughly 18%. But those numbers will only carry weight once the audit is finalised and the first-quarter report — due soon after the testat — can be verified on a clean basis.

Technical Picture Remains Fragile

The stock closed on Friday at €24.92, down 1.1% on the day and 8.78% on the week. That weekly drop follows a sharp monthly rally of 41.11%, illustrating the volatility that now defines Gerresheimer equity. The price sits above its 50-day moving average of €21.03 but below the 200-day line at €27.37. The near-term support at €24.50 is being tested.

With an oversold RSI, a heavy short interest, and a pending audit date far out on the calendar, Gerresheimer presents a classic tug-of-war: value hunters see a bargain, but prudent investors demand proof. The next real check mark won’t come until mid-2026 — unless the Centor sale changes the equation sooner.